Fundz
Following Moma Therapeutics?

Get the free weekly contract digest

The latest new contracts, like Moma Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Bayer and MOMA Therapeutics Enter Collaboration and License Agreement in Oncology

Oct 08, 2024•over 1 year ago

Contract Type

partnership

CambridgeBiotechnologyHealth CareScience And Engineering

Description

Bayer and MOMA Therapeutics have entered into a collaboration and license agreement to develop and commercialize a small molecule oncology program based on MOMA’s proprietary KNOMATIC™ platform. Bayer will gain access to the program itself along with results generated via MOMA’s KNOMATIC™ platform. This partnership aims to accelerate the development of innovative therapies that can make a meaningful difference in cancer treatment.

Company Information

Company

Moma Therapeutics

Location

Cambridge, Massachusetts, United States

About

MOMA Therapeutics is committed to discovering the next generation of precision medicines by targeting molecular machines that underlie human disease. Bringing together seminal scientific advancements in biochemistry, biophysics, structural biology, chemistry and functional genomics, the company is establishing a platform to exploit a key vulnerability inherent to all enzymes in the class: their dependence on well-coordinated, stepwise changes in protein conformation. By focusing this platform on disease-causing targets, MOMA aims to develop high impact, precision medicines for patients with unmet medical needs. MOMA Therapeutics is a private company launched in 2020 and is financed by world-class biotech investors, including a prestigious group of life sciences investors.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Moma Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.